Global Acne Vulgaris Pipeline Overview and Outlook 2020: Drugs, Companies, Clinical Trials, R&D Updates and More -

DUBLIN--()--The "Acne Vulgaris Pipeline Research Monitor, 2020 - Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Outlook" report has been added to's offering.


Acne Vulgaris is one of the widely researched conditions during 2020 with 42 companies actively focusing on realizing pipeline's potential. Development of Acne Vulgaris medicines is identified as integral to the strategy of the majority of companies operating in the industry.

Global Acne Vulgaris market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates. Increasing number of companies are assessing the feasibility of developing treatment options for Acne Vulgaris.

Good progress is anticipated during 2020 and 2021 with Acne Vulgaris pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials. Acne Vulgaris pipeline continues to expand and progress with novel mechanisms and diverse routes of administration being tested by companies.


The Acne Vulgaris pipeline Research Monitor, 2020 report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.

This Acne Vulgaris pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.

The competitive intelligence report on Acne Vulgaris presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Acne Vulgaris pipeline. Information on R&D pipeline updates, results of key clinical trials are also included in the report.


Acne Vulgaris development pipeline including projects in early- and late-stage development are detailed in the report. Details of clinical trial data and submissions to regulatory authorities are also provided. For the drug candidates included in the report, the following information is provided:

  • Current Status of Development including phase advancements, regulatory approvals of phases, acquisitions, licensing and technology transfers, product launches in various markets, and others.
  • Phase of development
  • Mechanism of Action
  • Route of Administration
  • Companies involved including originator, licensing companies, developer, investors, and others
  • New molecular entity details
  • Orphan drug designation and other special status provided by regulators


Both small size and large size pharmaceutical companies are investing their resources in Acne Vulgaris drug development operations. Further, financial institutions are extending support to small pharmaceutical companies, universities, and other researchers for the development of treatment of Acne Vulgaris. Partnerships and acquisitions are also increasingly observed in the pipeline.

This research report presents an analysis of 42 Acne Vulgaris companies including company overview, key snapshot, contact information, and their strategies on accelerating Acne Vulgaris pipeline development. Mid-stage and early portfolios of these companies are analyzed in detail in the report.

Reasons to Buy

  • The current market conditions are forcing companies and investors worldwide to prioritize their investments and accelerate pipeline candidates only through careful quantitative assessment.
  • This research work assists decision makers in pharmaceutical companies towards successful pipeline development through critically evaluated pipeline data
  • Buyers can identify most promising drug candidates for treatment of Acne Vulgaris
  • It allows users to strengthen their pipeline through acquisitions, licensing and collaborations
  • Users can estimate possible delays in the delivery of pipeline or launch of new products
  • Stay ahead of competition through understanding their pipeline progression, strategies and outlook
  • The report details all the pipeline candidates under investigation in various stages of development from Phase I through to Phase III to enable business development managers to understand the impact of new launches.
  • Optimize your licensing and technology transfer strategies through identification of prospect partners

Companies Analyzed (A-Z)

  • Allianz Pharmascience Ltd
  • Amgen Inc
  • AOBiome LLC
  • Avecho Biotechnology Ltd
  • Bausch Health Companies Inc
  • Biomimetix JV LLC
  • Boston Pharmaceuticals Inc
  • Botanix Pharmaceuticals Ltd
  • Cassiopea SpA
  • Cutanea Life Sciences Inc
  • Daewoong Co Ltd
  • Dermata Therapeutics LLC
  • Dermavant Sciences Inc
  • Devonian Health Group Inc
  • ELORAC Inc
  • Gage Development Company LLC
  • Innovation Pharmaceuticals Inc
  • Johnson & Johnson
  • Kalytera Therapeutics Inc
  • Lee's Pharmaceutical Holdings Ltd
  • Melinta Therapeutics Inc
  • Menlo Therapeutics Inc
  • Mimetica Pty Ltd
  • Naked Biome Inc
  • Novabiotics Ltd
  • Novartis AG
  • Origimm Biotechnology GmbH
  • Ortho Dermatologics Inc
  • Phagelux Inc
  • Phi Therapeutics Inc
  • Photocure ASA
  • Promius Pharma LLC
  • Provectus Biopharmaceuticals Inc
  • Revive Therapeutics Ltd
  • Riptide Bioscience Inc
  • Sebela Pharmaceuticals Inc
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
  • Sol-Gel Technologies Ltd
  • Timber Pharmaceuticals
  • Union Therapeutics AS
  • Verge Therapeutics Inc
  • Vyome Therapeutics Inc

For more information about this report visit

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900